Disruption of the pentraxin 3/CD44 interaction as an efficient therapy for triple-negative breast cancers.

ABSTRACT: Due to the heterogeneity and high frequency of genome mutations in cancer cells, targeting vital protumour factors found in stromal cells in the tumour microenvironment may represent an ideal strategy in cancer therapy. However, the regulation and mechanisms of potential targetable therapeutic candidates need to be investigated. An in vivo study demonstrated that loss of pentraxin 3 (PTX3) in stromal cells significantly decreased the metastasis and growth of cancer cells. Clinically, our results indicate that stromal PTX3 expression correlates with adverse prognostic features and is associated with worse survival outcomes in triple-negative breast cancer (TNBC). We also found that transforming growth factor beta 1 (TGF-β1) induces PTX3 expression by activating the transcription factor CCAA

SUBMITTER: Hsiao YW 

PROVIDER: S-EPMC8797470 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature